Durin Technologies
Durin Life Sciences is a biotechnology company founded in 2010, focused on the early detection of complex diseases through innovative blood tests. Their flagship product line, Duritect™, utilizes autoantibody blood tests combined with machine learning to assess the risk of Alzheimer's disease (Duritect-AD™) and Parkinson's disease (Duritect-PD™). These tests are designed to be minimally invasive, accurate, and provide rapid results, aiming to facilitate early diagnosis and intervention for improved patient outcomes. The company has secured over $15 million in funding and holds 20 patents. Durin Life Sciences envisions their tests becoming a routine part of annual checkups, enabling physicians to detect diseases years before symptoms appear.
Durin Technologies
Durin Life Sciences is a biotechnology company founded in 2010, focused on the early detection of complex diseases through innovative blood tests. Their flagship product line, Duritect™, utilizes autoantibody blood tests combined with machine learning to assess the risk of Alzheimer's disease (Duritect-AD™) and Parkinson's disease (Duritect-PD™). These tests are designed to be minimally invasive, accurate, and provide rapid results, aiming to facilitate early diagnosis and intervention for improved patient outcomes. The company has secured over $15 million in funding and holds 20 patents. Durin Life Sciences envisions their tests becoming a routine part of annual checkups, enabling physicians to detect diseases years before symptoms appear.